These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28764888)

  • 1. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
    Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
    Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
    Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
    Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
    Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
    Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.
    Mitchell P; McAllister I; Larsen M; Staurenghi G; Korobelnik JF; Boyer DS; Do DV; Brown DM; Katz TA; Berliner A; Vitti R; Zeitz O; Metzig C; Lu C; Holz FG
    Ophthalmol Retina; 2018 Oct; 2(10):988-996. PubMed ID: 31047501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
    Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
    Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema.
    Rahimy E; Baker K; Thompson D; Saroj N;
    Ophthalmic Surg Lasers Imaging Retina; 2020 Apr; 51(4):226-234. PubMed ID: 32348539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID.
    Valentim CCS; Singh RP; Du W; Moini H; Talcott KE
    Ophthalmol Retina; 2023 Jan; 7(1):24-32. PubMed ID: 35843487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
    Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
    Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
    Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
    Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
    Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
    Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
    Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
    Ip MS; Zhang J; Ehrlich JS
    Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.